0001104659-21-021032.txt : 20210211
0001104659-21-021032.hdr.sgml : 20210211
20210211215830
ACCESSION NUMBER: 0001104659-21-021032
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210209
FILED AS OF DATE: 20210211
DATE AS OF CHANGE: 20210211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CAVANAUGH JAMES H
CENTRAL INDEX KEY: 0001013473
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0731
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37990
FILM NUMBER: 21622385
MAIL ADDRESS:
STREET 1: 265 HOTHORPE LANE
CITY: VILLANOVA
STATE: PA
ZIP: 19085
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LEAP THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001509745
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274412575
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 47 THORNDIKE STREET
STREET 2: SUITE B1-1
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617 252 4343
MAIL ADDRESS:
STREET 1: 47 THORNDIKE STREET
STREET 2: SUITE B1-1
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Dekkun Corp
DATE OF NAME CHANGE: 20110107
4
1
tm216410-3_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-02-09
0
0001509745
LEAP THERAPEUTICS, INC.
LPTX
0001013473
CAVANAUGH JAMES H
C/O LEAP THERAPEUTICS, INC.
47 THORNDIKE STREET SUITE B1-1
CAMBRIDGE
MA
02141
1
0
0
0
Warrant (Right to Buy)
1.95
2021-02-09
4
J
0
1154
A
2019-02-05
2026-02-05
Common Stock, $0.001 par value per share
1154
1154
I
See Footnote
These warrants to purchase common stock were acquired by the reporting person in connection with a transfer (the "Transfer"), for no consideration, of warrants to purchase common stock by HealthCare Ventures IX, L.P. ("HCVIX") to the limited partners of HCVIX, including the reporting person, on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P., the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX.
The warrants were acquired in connection with the purchase of an equal number of shares of common stock by HCVIX on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer.
/s/ Douglas E. Onsi, as attorney-in-fact for James Cavanaugh
2021-02-11